A Long-Term Study for Extended BMN 701 Treatment of Patients With Pompe Disease Who Have Completed BMN 701 Studies

Trial Profile

A Long-Term Study for Extended BMN 701 Treatment of Patients With Pompe Disease Who Have Completed BMN 701 Studies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs Reveglucosidase alfa (Primary)
  • Indications Glycogen storage disease type II
  • Focus Adverse reactions
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 21 Jul 2016 The trial was completed in Germany (end date: 2016-06-22).
    • 25 Feb 2015 Planned End Date changed from 1 Sep 2016 to 1 Sep 2018 as reported by ClinicalTrials.gov record.
    • 25 Feb 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top